MedClub by Dr. Jenn: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://drjennpb.com in June 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.

1. 1

   “Your compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B. Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.”

2. 2

   “Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503B, because retatrutide does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list.”

3. 3

   “There are no FDA-approved applications on file for your compounded retatrutide drug products. Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug.”

4. 4

   “The following claims regarding compounded semaglutide products appear on your website:”

5. 5

   “• “FDA Approved” • “USA Compounded” or “Custom Compounded” • “Generic Ozempic””

6. 6

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

drjennpb.com returned a live site on 2026-08-09 titled "Palm Beach's Best MedSpa & Anti-Aging Clinic", presenting a West Palm Beach practice with cosmetic-medicine, skin, PRP, men's health and physician-assisted weight-loss sections and a booking flow. That is a check of whether the site is up; it is not a check of anything the letter alleges, and no attempt was made here to establish what the site offers today.

Two claims sat on one website, and the gap between what they promised and what existed is the whole lesson. On one page, "FDA Approved" — two words, no product named, no application referenced. On another, a compounded product built from a substance for which FDA has approved no application at all, and which does not appear on either of the two lists that would let a compounder use it lawfully without one. A reader had no way to tell those pages apart. Both were written in the same voice, on the same site, behind the same checkout, and "FDA Approved" is not a phrase that comes with a footnote telling you which product it belongs to. That asymmetry is the thing to carry away: approval language is cheap to write and expensive to verify, and the more categorically it is stated — "FDA Approved", full stop — the less it actually says. The verifiable version always has three parts: the product, the use, and the application holder. If a page cannot supply all three, the claim is not checkable, and a claim you cannot check is not evidence, whatever it costs. Note what this letter does not say. It makes no finding that anything was contaminated, badly made, or unsafe; approval status and product quality are separate questions and FDA addressed only the first. It is not a recall, a fine or a charge, and it has not been closed out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence MedClub by Dr. Jenn failed to respond.